Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide, Toripalimab, and Anlotinib in R/M Nasopharyngeal Carcinoma
NCT07320963Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Mar 2026
- Primary completion
- Mar 2027
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of tucidinostat in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
tucidinostat
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT07320963.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07320963.